Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON) (“Disc”), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that, after a distinguished 28-year career, including over 6 years at Disc, Brian MacDonald, MB, ChB, PhD, will be retiring from his role as Chief Innovation Officer. Dr. MacDonald plans to stay involved with Disc, transitioning from his current role to become Chair of Disc’s Scientific Advisory Board.
Related news for (IRON)
- Power Hour Pulse: From Helium Hype to Quantum Defense — Stocks to Watch into the Close
- Morning Movers & Moonshots: VirnetX Rockets, Carbon Revolution Accelerates, and Disc Medicine Grabs FDA’s Fast Track
- Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)
- Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
- Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress